Iovance's Amtagvi Shows 50% Response in Sarcoma, Plans 2026 Trial
IOVA has more than doubled off its 52-week low of $1.639.
Summary
Iovance Biotherapeutics is expanding its key TIL therapy, Amtagvi, into new tumor types, reporting a significant 50% response rate in aggressive soft-tissue sarcomas and planning a new trial for 2026. This clinical update is a strong positive signal for Amtagvi's broader market potential and builds on the company's recent momentum from its successful commercial launch and strong 2025 financial results. Separately, UBS raised its price target for Iovance to $4.00 from $2.00, indicating a positive re-evaluation, though the new target is currently below the stock's trading price of $4.41.
At the time of this announcement, IOVA was trading at $4.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $1.64 to $4.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.